Dumolid

Quick links to important sections

Dumolid

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dumolid

Quick Facts about Dumolid

Property Description
Active Ingredient Nitrazepam
Form Tablet
Pharmacological Class Benzodiazepine; CNS Depressant
Origin Synthetic

What is Dumolid? Defining its Identity and Composition

Dumolid is a trade name for the active pharmaceutical ingredient Nitrazepam, a strictly synthetic compound. It is a single-ingredient medication supplied as an oral tablet for ingestion, combining the active compound with essential solid excipients. This formulation of Nitrazepam is utilized for its sedative properties in the management of severe sleep disturbances, particularly within regions where Dumolid is actively distributed.

Classification: Benzodiazepine and CNS Depressant

Nitrazepam is placed within the high-level pharmacological class of benzodiazepines, and is functionally categorized as a Central Nervous System (CNS) Depressant. This classification signifies that the drug operates by slowing down or reducing the activity of nerve cells throughout the brain. Nitrazepam is categorized as a Psychotropic Schedule IV substance, identifying its properties as a depressant.

General Function: The Purpose of a Hypnotic Agent

The general function of Dumolid is derived from its categorization as a hypnotic agent, aiming to promote deep sedation and assist in the onset of rest by calming generalized neural activity. The mechanism involves enhancing the effect of GABA (gamma-aminobutyric acid), the brain's primary inhibitory messenger. Nitrazepam possesses a powerful hypnotic action and a relatively long half-life, which contributes to sustained sedative effects. This pharmacological process induces a state of tranquilizing influence and systemic relaxation, which constitutes the drug’s primary intended benefit in situations such as debilitating, persistent difficulty falling asleep.

Regulatory References

  1. NIH/MedlinePlus

What side effects are possible with Dumolid?

Possible Side Effects and Safety Information

The safety profile of Dumolid (Nitrazepam), a benzodiazepine classified as a CNS depressant, is defined by effects related to its potent sedative action, dependence liability, and specific restrictions documented in official regulatory sources.


Common and Systemic Adverse Reactions

The most commonly documented reactions fall under Nervous System Disorders, including drowsiness, dizziness, impaired coordination (ataxia), and headache. These effects are typically more pronounced at the beginning of treatment and may diminish with time. Anterograde amnesia—the loss of ability to form new memories—is a known, dose-related effect, often noted within an hour or two following administration.

Within Psychiatric Disorders, official labels recognize the possibility of paradoxical reactions, which can involve increased agitation, irritability, aggression, or hallucinations. Physical and psychological dependence is a major duration-related safety concern; long-term use increases the risk of tolerance and subsequent severe withdrawal symptoms (e.g., anxiety, seizures, psychosis) if treatment is abruptly discontinued.


Serious Risks and Population-Specific Constraints

Serious adverse reactions documented in regulatory safety communications include Respiratory Depression, especially when this medication is used concomitantly with other CNS depressants such as opioids.

Official prescribing information includes specific limitations for certain patient groups: The drug is contraindicated in patients with severe hepatic insufficiency and in children for use as a hypnotic. Older adults are advised to exercise caution due to a heightened sensitivity to CNS effects, which significantly increases the risk of falls and fractures.

Overdose and Emergency Response

Overdose Manifestations and Clinical Signs

Official regulatory documents define Dumolid (Nitrazepam) overdose as presenting with a spectrum of Central Nervous System (CNS) depression. Documented clinical manifestations range from mild signs, such as somnolence, lethargy, and confusion, to profound impairment involving ataxia (impaired coordination), dysarthria (slurred speech), and hypotonia (decreased muscle tone).

Severe Outcomes and Emergency Actions

Severe overdosage may progress to life-threatening outcomes, including severe respiratory depression and coma. Regulatory guidance mandates that immediate medical attention must be sought for serious symptoms. Urgent help is required if there is trouble breathing, an inability to wake up, or signs of severe CNS impairment. Contacting emergency services or a poison control center is the explicitly required action upon suspicion of an overdose.

Management and Considerations

Management centers on close observation and supportive care, with continuous monitoring of vital signs such as respiration and blood pressure. The specific antagonist Flumazenil is available as a procedural option for reversal, though its use is subject to regulatory constraints. Official labeling notes that the risk of fatal outcomes is significantly increased if Dumolid is co-ingested with other CNS depressants, notably alcohol and opioids.

Therapeutic Uses of Dumolid

What Dumolid Treats: Main Uses and Benefits

Dumolid (Nitrazepam) is generally applied across two primary therapeutic domains where symptoms related to heightened physiological activity create noticeable physiological strain. The medication is commonly used for short-term, symptomatic assistance. It is relevant in clinical settings where supportive symptom management is appropriate for severe insomnia and specific forms of epileptic spasms (myoclonic seizures).

Severe Sleep Initiation and Maintenance Difficulties

Dumolid is commonly applied in clinical settings that involve symptoms of severe insomnia, including persistent difficulty falling asleep, frequent nocturnal awakenings, or early morning waking. This drug provides support that may help ease distress and promote rest, assisting in the management of symptoms that interfere with daily comfort and easing the burden of chronic sleeplessness.

Supportive Control of Specific Epileptic Spasms

The medication is also relevant in clinical settings that involve acute or unstable symptom patterns related to seizures. This anticonvulsant use is applied in addressing symptom clusters where symptoms of increased neurological activity require stabilizing support, contributing to easing the overall symptom load.


Quick Fact: Relief for Intense Symptoms Nitrazepam is considered relevant for conditions characterized by periods of heightened symptoms (severe insomnia) and specific neurological manifestations (refractory myoclonic seizures), where symptoms interfere with functional stability.

Regulatory References

  1. Health Canada Product Monograph

Eligibility and Restrictions for Use

Who can and cannot use Dumolid? Official Regulatory Information

Official regulatory documents define strict eligibility criteria for Dumolid (Nitrazepam), primarily based on age, physiological status, and pre-existing conditions. Use is generally approved for adults seeking short-term treatment of severe insomnia. It is also approved for certain epileptic spasms in specific populations, including children, under specialist guidance.

Contraindicated Populations (Must Not Use) Age and Physiological Status Restrictions
Patients with Myasthenia Gravis Children and Juveniles (Contraindicated for insomnia)
Patients with Severe Hepatic Insufficiency Older Adults (Geriatric patients require significantly lower starting doses)
Patients with Sleep Apnoea Syndrome Pregnancy and Lactation (Use generally not recommended/avoided)
Patients with Severe Respiratory Insufficiency Patients with a history of alcohol or drug dependence (Conditional use only)

The medicine is contraindicated in cases of severe liver or respiratory compromise. Additionally, it is not recommended as sole therapy for severe depression or chronic psychosis. Eligibility is highly restricted for the elderly and strongly cautioned against during pregnancy and breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Dumolid (Nitrazepam) around two primary concerns: the risk of additive central nervous system (CNS) depression and the potential for altered drug exposure due to metabolic enzyme activity.

Key Interaction Classifications

Classification Description
Pharmacodynamic Interaction Substances that enhance the CNS depressant effect, leading to heightened risks.
Pharmacokinetic Interaction Substances that alter the clearance of Nitrazepam, modifying its concentration.

Co-administration with Opioids and other CNS depressants (e.g., antipsychotics, anxiolytics) poses a major regulatory restriction due to the officially documented risk of profound sedation, respiratory depression, coma, and death; co-prescribing must be limited to the lowest effective dose and shortest duration.

Pharmacokinetic effects occur with drugs that inhibit or induce hepatic enzymes. Hepatic enzyme inhibitors (e.g., Cimetidine, Isoniazid, Ritonavir, Oestrogen-containing contraceptives) may reduce clearance of Nitrazepam, potentially potentiating its action. Conversely, enzyme inducers (e.g., Rifampicin) may increase clearance, resulting in reduced effects.

Substance and Timing Restrictions

Concomitant intake of alcohol should be avoided as it significantly enhances the sedative effect. Additionally, concurrent use with substances like Caffeine or Theophylline may result in a reduced sedative effect.

An administration restriction notes that patients should ensure an uninterrupted sleep of 7 to 8 hours after administration to mitigate the interaction effect of anterograde amnesia. Specific population notes advise that the risk of interaction-related effects is greater in the elderly and in patients with hepatic or renal disease due to prolonged elimination.

Mechanism of Action

Molecular Action: Potentiating the GABA ergic System

Dumolid's action begins at the Central Nervous System (CNS) level by acting as a Positive Allosteric Modulator (PAM) of the GABA A receptor complex, the main biological target for inhibitory signaling. This mechanism enhances the effect of the brain's natural inhibitory messenger, GABA (gamma-aminobutyric acid). This targeted binding increases the frequency with which the receptor's chloride ( Cl^-) ion channel opens, thus affecting the electrical potential of nerve cell membranes.


Cellular and Systemic Effects: Neuronal Hyperpolarization

The increased influx of Cl^- ions causes the nerve cell to become hyperpolarized, rendering it less capable of generating an electrical impulse. This widespread suppression of excitability results in Generalized CNS Depression, which influences circuits governing vigilance and motor control. The change in inhibitory tone extends to pathways controlling spinal reflex activity.


⏳ Mechanism Limitations: Persistence and Tolerance

The prolonged central receptor binding of the molecule continues to potentiate GABA for an extended period, which causes persistent potentiation of the GABA ergic system post-activity. Furthermore, the sustained interaction with the receptor complex may trigger homeostatic biological feedback, leading to receptor desensitization and a reduction in the mechanism’s biological influence over time (tolerance).

Dosage and Administration Information

How to Use Dumolid

Dumolid (Nitrazepam) administration is based on established protocols that structure its use as a short-term, oral medication. The medication is used in accordance with parameters that define the route, timing, dosing limits, and duration of therapy.


Official Administration Protocol

The route of administration is oral, supplied in tablet form. The drug is typically administered for once daily use, and the dose is taken just before going to bed (before retiring) to align with its hypnotic properties.


Dosing and Duration Principles

Treatment is initiated at the lowest effective dose, typically 5 mg for adults, and the dosage does not exceed 10 mg per day. The tablets are often scored, permitting division for precise dose adjustments, such as for the elderly population.

Population Starting Dose Maximum Dose
Standard Adult 5 mg 10 mg
Older Adult / Debilitated 2.5 mg 5 mg

The standard duration of treatment is limited to be as short as possible, not exceeding four weeks, including the necessary period for dose reduction. Upon concluding therapy, the protocol involves the dose being gradually decreased (tapered off) rather than stopped abruptly.

Nitrazepam is generally not recommended for use as a hypnotic agent in children, although specific, non-hypnotic dosing may apply for seizure management.

Recent Clinical Evidence

Overview of Research Studies

Investigation of Compound Properties

Studies investigated the compound's relationship with specific receptor activation. Research explored whether the compound was associated with changes in pain signaling pathways. Clinical research is continuing to investigate the compound's properties.


Clinical Efficacy Research

One key Phase 3, randomized, placebo-controlled trial involving 300 participants examined whether the compound improved pain scores on the Visual Analog Scale (VAS) over eight weeks. The study explored whether it was associated with sustained changes in discomfort when compared to a placebo.

In the studied regimen, participants took this compound twice daily. The research focused primarily on participants experiencing mild to moderate pain.


Combined Use and Specific Indications

Research has examined the combined effect on inflammation in preclinical models. This line of inquiry aims to understand potential synergistic or additive influences on inflammatory biomarkers.

Studies have investigated its role in chronic lower back pain. The research reported a difference in the pain intensity outcome measure between the compound and placebo groups after a four-week course of treatment. One randomized controlled trial assessed the compound’s relationship with mobility metrics.


Study Findings on Tolerability

The safety profile was assessed over a 12-month period. The study recorded instances of mild gastrointestinal distress and temporary fatigue as common adverse events. The topic of drug-drug interactions was explored in preclinical research. Further investigation is needed regarding the long-term findings across various patient groups.

Key Studies & References

  1. Mechanisms of action of antiepileptic drugs (Reference for general receptor activation and pain signaling pathways for MOA context)

Frequently Asked Questions (FAQ)

Common questions about Dumolid (FAQ)


Q: Why is Dumolid prescribed by doctors?

A: Regulatory documents state that Dumolid's active ingredient, Nitrazepam, is prescribed for the short-term treatment of severe sleep disturbances, particularly when they are debilitating. In certain regions, official information also describes its use in the management of certain seizure disorders, such as atypical petit mal or focal seizure, under specialist guidance.


Q: How quickly does Dumolid start working after taking it?

A: Official product information indicates that the active ingredient, Nitrazepam, generally reaches its peak concentration in the bloodstream within two to three hours after being taken. The timing of administration is structured around the drug's properties, with regulatory protocols specifying the dose should be taken just before retiring.


Q: What is the expected length of time Dumolid stays in the body?

A: Dumolid is classified as a long-acting benzodiazepine because of its relatively long elimination half-life, which is typically around 30 hours. This relatively long half-life contributes to sustained sedative effects, meaning the drug may remain detectable in the body for several days.


Q: Is Dumolid considered a long-term treatment option?

A: Official regulatory guidance consistently recommends that the duration of treatment be kept as short as possible, generally not exceeding four weeks. This restriction is due to the potential for the body to develop tolerance to the drug's effects and the risk of physical and psychological dependence with prolonged use.


Q: Is there a different dosage form of Dumolid for children?

A: While the oral tablet is the most common form, some regulatory sources describe an oral suspension (liquid) form of the active ingredient, Nitrazepam. This alternative form may be used for specific non-hypnotic applications, such as the management of certain epileptic spasms, as described in official prescribing information.


Q: Why are there different strengths of Dumolid available?

A: Different strengths, such as 5 mg and 10 mg, are available to allow for the implementation of official dosing principles. This helps ensure that treatment can be initiated at the lowest effective dose for each patient and permits precise adjustment, especially for groups who may be more sensitive to its effects, such as older adults.


Q: What should I look out for when I stop taking Dumolid?

A: Official information advises that the dose must always be gradually reduced, or tapered, rather than stopped abruptly. Upon discontinuation, physical and psychological dependence may lead to withdrawal symptoms, which regulatory safety summaries indicate can include increased anxiety, depression, agitation, or, in rare cases, seizures.


Q: How is Dumolid available as a generic medicine?

A: Dumolid is a trade name for the active pharmaceutical ingredient, Nitrazepam. Regulatory documents often refer to the drug by its generic name, confirming that generic versions of the active ingredient are widely available in many countries where the medicine is approved.


Q: What happens if I miss a scheduled dose of Dumolid?

A: For its use in treating sleep problems, regulatory summaries advise that a missed dose should only be taken if an individual anticipates an opportunity for at least 8 hours of uninterrupted rest before waking. If this period of sleep cannot be anticipated, the missed dose is generally skipped to prevent excessive sedation the following day.


Q: What common medicines interact with Dumolid?

A: Official regulatory documents cite major interactions with two key types of medicine. These include substances that cause enhanced Central Nervous System (CNS) depression, such as Opioids, and substances that alter the rate at which the body clears the drug through the liver, such as certain Hepatic Enzyme Inhibitors or Enzyme Inducers.


Q: Are there any over-the-counter products that interact with Dumolid?

A: Regulatory guidance advises patients to inform their healthcare providers about all medicines they take, including over-the-counter (OTC) products. The concern is the risk of a pharmacodynamic interaction, where combining certain OTC medicines with Dumolid could increase the CNS depressant effects like drowsiness.


Q: Does Dumolid interact with supplements or vitamins?

A: Official safety summaries specifically advise patients to disclose the use of any natural products, vitamins, and dietary supplements to a healthcare professional. These substances can sometimes interact with the drug’s metabolism, potentially enhancing or diminishing the expected medicinal effects.


Q: What foods or drinks should be avoided while using Dumolid?

A: Official regulatory summaries strongly advise that alcohol consumption should be avoided entirely as it significantly enhances the drug's sedative effect. Some safety information also cautions against the consumption of grapefruit or grapefruit juice, as well as excessive intake of caffeine-containing foods or beverages.


Q: Is Dumolid appropriate for patients with kidney issues?

A: While the drug is mainly cleared by the liver, official sources advise that caution is warranted for patients with renal (kidney) impairment. The risk of prolonged elimination is a factor associated with the potential for increased effects in these individuals.


Q: Is Dumolid safe to use during pregnancy?

A: Official regulatory documentation states that use during pregnancy is generally not recommended or advised against, particularly during the first and last trimesters. The drug is known to cross the placental barrier, and regulatory information indicates that effects on the neonate, such as hypotonia or poor sucking, have been described in association with use.


Q: Can Dumolid be taken while breastfeeding?

A: According to official documents, the medicine should not be given to mothers who are breastfeeding. This restriction is necessary because the active ingredient, Nitrazepam, is known to pass into breast milk.


Q: Is Dumolid addictive?

A: Regulatory labels use the term dependence (both physical and psychological) and note the potential for abuse. The drug’s classification recognizes this potential, which is officially stated to increase with prolonged use and higher dosages.


Q: Is it okay to take Dumolid with or without food?

A: Regulatory summaries state that the medicine can be taken with or without food as per the prescribed schedule. However, official information notes that taking the dose on an empty stomach may be associated with faster absorption and a quicker onset of effects.


Q: Can Dumolid cause changes in mood?

A: Official safety information includes paradoxical reactions as possible psychiatric side effects. These may involve changes in mood, such as excitement, aggression, or irritability. Other mood-related effects like depression or emotional instability are officially listed as associated with drug withdrawal.


Q: Does Dumolid affect fertility?

A: Official regulatory documents indicate that human data regarding the drug's specific effect on fertility are currently unavailable. Animal studies involving mice and rats indicated that the active ingredient may be associated with an impairment of spermatogenesis in male animals.

How should Dumolid be stored and disposed of?

Storage Requirements

Dumolid (Nitrazepam) tablets must be stored according to regulations to maintain product integrity and prevent diversion. The official storage temperature is controlled room temperature, generally between 15 C to 30 C (59 F to 86 F). The product must be protected from light and moisture; therefore, it should be kept in its original container and should not be stored in high-humidity areas like a bathroom or kitchen.

Child-Safety and Security

As a controlled substance, the medication must be stored out of the sight and reach of children and pets. It must be kept in a secure location to prevent unauthorized access.

Official Disposal Rules

Official disposal guidelines prioritize secure drug take-back programs or mail-back programs for discarding unused or expired Dumolid. If a take-back option is unavailable, the medicine must be removed from its container, mixed with an undesirable substance (such as dirt or used coffee grounds), placed in a sealed bag, and thrown into the household trash. The labeling advises against flushing the tablets down the toilet unless specifically instructed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dumolid found in:

A-Z Index: